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Emerging roles of pathogens in
Alzheimer disease
Judith Miklossy*
Chronic spirochetal infection can cause slowly progressive dementia, cortical
atrophy and amyloid deposition in the atrophic form of general paresis. There
is a significant association between Alzheimer disease (AD) and various types
of spirochete (including the periodontal pathogen Treponemas and Borrelia
burgdorferi), and other pathogens such as Chlamydophyla pneumoniae and
herpes simplex virus type-1 (HSV-1). Exposure of mammalian neuronal and
glial cells and organotypic cultures to spirochetes reproduces the biological
and pathological hallmarks of AD. Senile-plaque-like beta amyloid (Aβ)
deposits are also observed in mice following inhalation of C. pneumoniae in
vivo, and Aβ accumulation and phosphorylation of tau is induced in neurons
by HSV-1 in vitro and in vivo. Specific bacterial ligands, and bacterial and
viral DNA and RNA all increase the expression of proinflammatory
molecules, which activates the innate and adaptive immune systems.
Evasion of pathogens from destruction by the host immune reactions leads
to persistent infection, chronic inflammation, neuronal destruction and Aβ
deposition. Aβ has been shown to be a pore-forming antimicrobial peptide,
indicating that Aβ accumulation might be a response to infection. Global
attention and action is needed to support this emerging field of research
because dementia might be prevented by combined antibiotic, antiviral and
anti-inflammatory therapy.
Alzheimer disease (AD) is characterised by a
slowly progressive decline of memory and
cognition. Alzheimer described the characteristic
cortical senile plaques and neurofibrillary
tangles in the brain of a 51-year-old woman
with presenile dementia (Refs 1, 2). Because the
presenile form, with onset before the age of 65,
is identical to the most common form of senile
dementia, today, the term AD is used for the
designation of both presenile and senile cases
(Refs 3, 4).
Senile plaques were first described by Blocq
and Marinesco (Ref. 5). Redlich (Ref. 6) first
observed senile plaques in the brains of two
patients with senile dementia. Recently,
particularly from the use of the Gallyas silver
technique (Ref. 7), neuropil threads or curly
fibres were recognised as further characteristic
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lesions of AD. Granulovacuolar degeneration is
another typical alteration of neurons (Ref. 8).
Other important features include neuronal and
synaptic loss (Ref. 9), Hirano bodies, reactive
astrocytosis and microgliosis.
AD is a form of amyloidosis. The amyloid
substance aggregated in the brain is a small,
∼4 kDa amyloid beta peptide (Aβ). It is released
by β- and γ-secretase cleavage from a larger
120 kDa transmembrane amyloid precursor
protein (APP) (Refs 10, 11) and was purified and
partially sequenced by Glenner and Wong
(Ref. 12). APP exhibits features of a glycosylated
cell-surface receptor and was shown to be a
proteoglycan core protein (Ref. 13). APP is
phylogenetically highly conserved and
constitutively expressed by various cells other
than neurons, including immune cells (Ref. 14).
Human platelets, peripheral lymphocytes and
leukocytes produce the major isoforms of APP,
and after activation, they secrete amyloidogenic
Aβ (Refs 15, 16, 17, 18).
Aβ1–42 has a higher ability to aggregate than
the shorter Aβ1–40 (Refs 19, 20). Aβ exists in
soluble nontoxic monomers, strongly toxic
soluble oligomers and in the form of less toxic
insoluble fibrils. The soluble oligomers of
Aβ1–42 are the most toxic (Refs 21, 22, 23, 24,
25, 26). They form annular or pore-like
structures that are indistinguishable from a
class of pore-forming bacterial toxins (Refs 24,
25, 27), which cause rapid calcium influx
through the targeted cell membranes (Refs 28,
29, 30). Recent in vitro and in vivo studies
showed that Aβ is an antimicrobial peptide
(AMP) that targets bacterial membranes
(Ref. 31). AMPs have proinflammatory activities
and have a role in innate immune responses
(Ref. 31).
Neurofibrillary tangles and neuropil threads
contain paired helical filaments (PHFs) (Refs 32,
33). The major component of PHFs is the
microtubule-associated protein tau, which is in a
pathological hyperphosphorylated state that
abolishes microtubule assembly (Refs 34, 35).
Sequestration of peptidyl-prolyl cis/trans
isomerase NIMA interacting 1 (PIN1) is one
theory that explains the formation of these
pathological fibrillar lesions (Ref. 36).
Various hypotheses have been proposed to
explain the pathogenesis of AD (Refs 37, 38, 39,
40, 41, 42, 43). A significant proportion of early-
onset AD is inherited as an autosomal dominant
trait (Ref. 44). Missense mutations of the APP
gene located on chromosome 21 (Refs 45, 46) are
responsible for 5% of all early-onset familial AD
cases (Ref. 44). Presenilin-1 (PS1) gene mutations
are most frequent in early-onset familial AD
(Refs 37, 47). More than 80 different PS1
missense mutations or amino acid deletions
have been identified (Refs 37, 47, 48, 49, 50).
Presenilin-2 (PS2) mutations are responsible for
another subset of early-onset familial AD
(Refs 47, 51). As originally shown by Hardy
(Ref. 39), mutations in these pathogenic genes
alter the processing of APP and result in an
increase in amyloidogenic Aβ1–42 and Aβ1–43
(Refs 50, 52, 53, 54, 55, 56, 57, 58, 59). The
epsilon 4 allele of apolipoprotein E (APOE ε4) is
an important risk factor for late-onset AD,
which also correlates with increased Aβ burden
(Ref. 60). Finally, there is an association between
AD and polymorphisms of various other genes,
which include a growing number of genes,
implicated in immune defence mechanisms
(Refs 61, 62).
The relation between the two major biological
markers of AD, Aβ (Refs 38, 41) and
hyperphosphorylated tau (Refs 34, 35), is not
clear. Soluble Aβ and tau strongly interact
(Ref. 63), and APP is expressed in neurofibrillary
tangles (Ref. 64), suggesting that these
apparently different pathologies are linked.
Alterations of various neurotransmitters,
neuropeptides and hormones are reported to
occur in AD (Refs 65, 66, 67, 68). The cholinergic
hypothesis is based on the alteration of
acetylcholine synthesis, transport and release
(Refs 69, 70). Oxidative damage to proteins,
lipids and nucleic acids (Refs 71, 72, 73, 74) and
mitochondrial dysfunction (Ref. 75) are also
significant contributors to the pathogenesis of
AD. The role of various metals, including
aluminium (Refs 76, 77) and iron (Ref. 78) was
proposed several decades ago. Direct modulation
of APP processing by metal ions, including Ca2+,
Zn2+, Fe2+/Fe3+ and Al3+, suggests that
disrupted metal homeostasis also leads to
increased APP levels (Ref. 79). The calcium
homeostasis hypothesis indicates that sustained
deregulation of cytosolic calcium represents the
common final pathway for neuronal death in AD
(Ref. 80). Dysregulation of ubiquitylation or
glycosylation processes (Refs 81, 82) has been
shown in AD. Vascular lesions, including
cerebral hypoperfusion and disturbed brain
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microcirculation, are also important factors
(Refs 83, 84, 85, 86, 87, 88, 89, 90, 91). Factors
representing a risk for atherosclerosis (Refs 92,
93), are also risk factors for AD. Early
involvement of the olfactory system in AD
(Ref. 94) led to the ‘olfactory hypothesis’, which
suggests that putative pathogenic agents might
access the brain by the olfactory pathways
(Refs 95, 96, 97). Deregulation of various
signalling pathways, apoptosis, craniocerebral
trauma, exercise, environmental and nutritional
factors, among others, are also implicated in the
pathogenesis of AD.
The critical role of chronic inflammation and
the importance of interleukin (IL)-1 signalling
in AD is now widely recognised (Refs 98,
99, 100). A series of inflammatory mediators,
including cytokines, chemokines, proteases,
adhesion molecules, free radicals, pentraxins,
prostaglandins, anaphylatoxins and activated
complement proteins, is present at the site of
cortical lesions in AD (Refs 101, 102, 103). The
membrane attack complex (MAC, C5b-9) is also
associated with plaques, tangles and neuropil
threads (Refs 100, 104). Use of nonsteroidal anti-
inflammatory drugs reduces the risk of AD
(Refs 105, 106, 107, 108).
Nearly a century ago, Fischer, Alzheimer and
their colleagues (Refs 2, 109) discussed the
possibility that microorganisms could have a
role in the formation of senile plaques. That a
slow-acting unconventional infectious agent,
acquired at an early age and requiring decades
to become active, might be involved in AD was
considered by several authors (Refs 110, 111). A
growing number of recent observations indicate
that infectious agents are involved in the
pathogenesis of AD. Here, I review historical
and recent observations on infectious agents
related to AD and analyse the significance of the
association and causal relationship.
Analogies between AD and the atrophic
form of general paresis
Historical observations show that the clinical and
pathological hallmarks defining AD are similar to
those occurring in the atrophic form of general
paresis, a chronic bacterial infection (Refs 112,
113, 114, 115, 116, 117, 118). In 1913, Noguchi
and Moore (Ref. 119) provided conclusive
evidence that spirochetes are responsible for
slowly progressive dementia, cortical atrophy
and local amyloidosis.
General paresis of the insane, paretic dementia
or dementia paralytica is a chronic
meningoencephalitis caused by the direct
invasion of brain parenchyma by Treponema
pallidum. Two forms are distinguished: the
infiltrative and the atrophic form (Refs 114, 117).
In the infiltrative form, mood disorders and
psychosis predominate, and lymphoplasmocytic
meningoencephalitis is the characteristic
pathology (Refs 117, 118). The atrophic form is
characterised by slowly progressive dementia
and cortical atrophy, which is accentuated in the
frontotemporal regions (Refs 114, 115).
Spirochetes form masses, plaques or colonies
(Fig. 1) and disseminate as individual filaments,
which are restricted to the cerebral cortex
(Fig. 1) (Refs 114, 115). These spirochetal masses
and individual spirochetes are morphologically
identical to senile plaques (Fig. 1) and neuropil
threads (Fig. 1). Pacheco e Silva (Refs 114, 115),
reported that the number of spirochetes and
spirochetal ‘plaques’, which are numerous in the
hippocampus and frontal cortex, increases in
parallel with the severity of cortical atrophy
(Refs 114, 115). Lymphoplasmocytic infiltrates
are absent. Severe neuron loss is accompanied
by reactive microgliosis and astrocytosis and by
accumulation of ‘paralytic iron’ (Ref. 120). The
occurrence of neurofibrillary tangles is also
documented in general paresis (Refs 113, 118,
121, 122), and the local amyloid (Ref. 123), as in
AD, consists of Aβ (Ref. 124).
Analogies between AD and other age-
related chronic inflammatory disorders
Pathogens can produce slowly progressive
chronic diseases. Following the pioneering
work of Warren and Marshall (Ref. 125), it is
today established that Helicobacter pylori causes
stomach ulcers. Infectious agents are also linked
to atherosclerosis, cardio- and cerebrovascular
disorders (Refs 126, 127, 128, 129, 130, 131,
132, 133, 134), chronic lung diseases (Refs 135,
136, 137), inflammatory bowel diseases and
neuropsychiatric disorders (Refs 138, 139, 140,
141, 142, 143).
Chlamydophila (Chlamydia) pneumoniae (Refs 126,
127), H. pylori (Refs 128, 129) and several
periodontal pathogens, including invasive oral
spirochetes (Refs 130, 131) and herpes viruses,
have been found in human atherosclerotic
lesions. Some of them also enhanced
atherosclerosis in experimental animals
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(Refs 131, 132). These pathogens were also
reported to be associated with AD (Refs 144,
145, 146, 147, 148, 149, 150, 151).
Epidemiological studies have confirmed that
several of these chronic inflammatory disorders
are associated with AD (Refs 152, 153, 154, 155).
In addition, they are all linked to periodontal
polybacterial disorders, which are primarily
caused by Gram-negative bacteria (Refs 156, 157,
158, 159). Spirochetes and herpes viruses are
predominant periodontal pathogens (Refs 160,
161, 162, 163), and C. pneumoniae is a major upper
respiratory tract pathogen. An infectious origin
might give a comprehensive explanation of the
common cellular and molecular mechanisms,
inflammatory processes and common
inflammatory gene polymorphisms involved in
these chronic inflammatory disorders and AD
(Refs 61, 164, 165).
Evidence for the association of pathogens
with AD
Spirochetes
Spirochetes are Gram-negative, helical bacteria,
which possess endoflagella, taxonomically
distinguishing them from other bacteria. There
are over 200 different spirochetal species or
phylotypes (Ref. 166). Spirochetes are causative
agents of important human diseases such as
syphilis, pinta, yaws, bejel, Lyme disease,
Vincent angina, relapsing fever, leptospirosis,
ulcerative gingivitis and various periodontal
disorders (Ref. 167). The major Borrelia species
causing Lyme disease are B. burgdorferi
Distribution of spirochetes in the atrophic form of general paresis and in the 
frontal cortex of an Alzheimer disease patient with Lyme neuroborreliosis
Expert Reviews in Molecular Medicine © 2011 Cambridge University Press
a b
c d
Figure 1. Distribution of spirochetes in the atrophic form of general paresis and in the frontal cortex of
an Alzheimer disease (AD) patient with Lyme neuroborreliosis. Spirochetes form plaque-like masses (a,c)
and disseminate as individual filaments (b,d) in general paresis (a,b) and AD (c,d), which are identical to senile
plaques and curly fibres. (a,c) Bosma Steiner silver technique for the visualisation of spirochetes. (b)
T. pallidum-specific polyclonal antibody. (d) Gallyas silver technique. Scale bars: 50 μm (a), 40 μm (c),
10 μm (b,d). All images were obtained from previously published studies: a (Ref. 124); b (Ref. 175); c, d
(Ref. 149).
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(Ref. 170), B. afzelii, B. garinii and B. valaisiana.
Relapsing fever is caused by B. recurrentis. Oral
spirochetes are predominant periodontal
pathogens that are highly prevalent in the
population and comprise diverse Treponema
species (Refs 166, 171). Several are invasive
(Refs 172, 173): they include T. denticola, T.
socranskii, T. pectinovorum, T. amylovorum,
T. lecithinolyticum, T. maltophilum, T. medium
and T. putidum (Refs 166, 171, 174). T. vincentii
causes Vincent angina, a necrotising
fusospirochetal disease (Ref. 167).
Because spirochetes are strongly neurotropic
(Ref. 167), it was expected that several types of
spirochetes, in an analogous way to T. pallidum,
might cause dementia, plaque- and tangle-like
lesions, Aβ deposition and consequently might
be involved in the pathogenesis of AD. To detect
all types of spirochete, neutral techniques
need to be used (Ref. 146). Using dark-field
microscopy, spirochetes were detected in the
cerebrospinal fluid (CSF), in the blood and in
the brain in 14 definite AD cases tested
(Table 1). Spirochetes were not found in 13 age-
matched controls without any AD-type cortical
changes (Ref. 146). Silver-stained helically
shaped spirochetes were also detected by
electron microscopy. Spirochetes were isolated
from the cerebral cortex in these 14 AD cases
(Table 1), and in three of them, they were
cultivated from the brain in a selective medium
for B. burgdorferi (Ref. 146). Spirochetes were
detected and isolated from the brains of eight
additional AD cases derived from another
laboratory and in the blood of five living
patients with clinically diagnosed AD-type
dementia (Ref. 186; Table 1). Four healthy
controls did not show spirochetes. Taxonomical
analyses showed that the helically shaped
microorganisms belong to the order
Spirochaetales (Ref. 187). To ensure the
consistency of these results, the detection of
spirochetes was also performed using various
other techniques, including histochemistry, dark-
field microscopy, atomic force microscopy,
electron microscopy and immunoelectron
microscopy, immunohistochemistry using
spirochete and bacterial peptidoglycan (PGN)-
specific antibodies (Refs 146, 147, 149, 186, 187,
176, 175, 188, 189), and detection of specific and
nonspecific bacterial DNA (Refs 149, 176). PGN
is the building block of the cell wall of Gram-
negative and Gram-positive bacteria; however,
mycoplasma and chlamydiae lack detectable
PGN (Refs 190, 191). The morphology of
spirochetes detected by spirochete- or PGN-
specific antibodies is identical (Fig. 2; compare
also Fig. 7 G and H of Ref. 175). PGN-
immunoreactive spirochetes were detected in 32
definite AD cases and in 12 cases with mild or
moderate AD-type cortical changes.
Other authors found no evidence of spirochetes
in the brains of seven AD cases by dark-field or
electron microscopy (Ref. 192). However,
spirochetes were observed in the blood of one of
22 living patients with AD-type dementia
(Table 1). The spirochete observed by these
authors corresponded to the vegetative,
regularly spiral form. They suggested that it
could correspond to an oral spirochete. Whether
the atypical, pleomorphic spirochetal forms,
which commonly occur in infected tissues, blood
and CSF (Refs 167, 175, 177, 193), were
considered by the authors is not clear.
Periodontal pathogen Treponemas
Using molecular and immunological techniques,
six of seven periodontal Treponema species,
namely T. socranskii, T. pectinovorum, T. denticola,
T. medium, T. amylovorum and T. maltophilum,
were identified in the brains of AD patients
using species-specific polymerase chain reaction
(PCR; Table 1). At least one oral Treponema
species was present in 14 of 16 AD brains,
compared with 4 out of 18 controls (Ref. 147). T.
pectinovorum and T. socranskii antigens were
observed in 15 of 16 AD brains and in 7 of 18
controls. In the hippocampus and in the frontal
cortex. Six different Treponema species were
detected in one AD patient, five species in four,
four or three species each in one AD case, and
one species in seven AD brains. Two Treponema
species were observed in one control and one
species in the other three positive controls.
These results reinforce previous observations
(Ref. 146) and indicate that these periodontal
pathogen spirochetes, in an identical way to T.
pallidum and B. burgdorferi, have the ability to
invade the brain, persist in the brain, and cause
dementia, cortical atrophy and amyloid
deposition.
Borrelia burgdorferi
The causative agent of Lyme disease is transmitted
by the bite of infected ticks (Ref. 170). Neurological
complications occur in about 15% of affected
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Table 1. Detection of spirochetes in AD
Material Number Method AD Control Culture Serology Refs
All types
of spirochete
Brain 27 DF, HC, IHC Bl,
CSF EM, AFM
14/14 0/13a 14/14 ND (Bl 4/5) 146,187
Brain 12 DF 8/8 0/4a 8/8 ND 186
Blood 5 DF, Cult 5/5 ND ND 186
Brain 24 DNA-DAPI 20/20 0/4a ND ND 176
10b 10/10b 176
Brain 54 IHC 32/32 0/10a
12/12c
ND ND 188,189
ND ND
Brain 7 DF, EM 0/7 ND ND 192
Blood 28 1/22 0/6 ND ND 192
Total brain 102 64/71 0/31d P= 4.8 × 10−18
OR= 274d
95% CI= 32–11 345
Periodontal pathogen
spirochetes
Brain 34 PCR, IHC 15/16 6/18 ND ND 147
Total brain 34 15/16 6/18 P= 3.6 × 10−4
OR= 30
CI= 2.8–1364
Borrelia burgdorferi Brain 2 IHC, Cult 1/1 0/1 + ND 178
Brain 1 DF, IHC, Cult 1/1 + ND 199
Brain 10 EM, IHC, Wbl 0/6 0/4 – ND 185
Brain 27b Cult, IHC, EM Bl, CSF,
ISH, Serol 16SrRNA
3/14b 0/13b 3/14 2/14 146,149
Brain 1 IHC, Serol 1/1 ND 1/1 146
Brain 10 PCR, Cult 0/10 – ND 180
Brain 30 PCR 0/15 0/15 ND ND 181
Brain 34b PCR, seq 5/16b 1/18b ND ND 147
Brain 1 PCR 1/1 ND 1/1 179
Brain 11 PCR, ISH 7/10 0/1 ND 1/1 183, 184
Total brain 127 19/75 1/52 P= 2.9 × 10−4
OR= 17
CI= 2–732
All studies detecting
spirochetes
Brain 214 102/143 6/71 P= 1.5 × 10−19
OR= 26
CI= 10–80
Brain, blood, CSF 247 108/170 6/77d P= 1.1 × 10−17
OR= 20
CI= 8–60
Data reviewed in the literature with respect to the detection of all types of spirochetes using neutral techniques and the specific detection of periodontal pathogen
Treponemas and Bb. Results of the statistical analysis are given for each group and for all studies together. AD indicates number of AD cases positive for spirochetes/
number of AD cases analysed; Control indicates number of control cases positive for spirochetes/number of control cases analysed. AD, Alzheimer disease; Bl, blood;
CSF, cerebrospinal fluid; EM, electron microscopy; AFM, atomic force microscopy; DF, dark-field microscopy; HC, histochemistry (Warthin and Starry, Bosma-Steiner
silver stain for spirochetes); IHC, immunohistochemistry; ISH, in situhybridisation;PCR, polymerase chain reaction;Bb,Borrelia burgdorferi;Wbl,Western blot;P is exact
value of the significance calculated by Fischer test; OR, odds ratio; CI, 95% confidence interval; +, positive; –, negative; ND, not determined; seq, sequencing.
aControls without any AD-type changes.
bCases from previous studies, which were subtracted when the total number of cases of studies was considered.
cCases with mild or moderate AD-type cortical changes.
dWhere the number of positive controls was zero, in order to calculate the OR and 95% CI, one positive case was added to the control group.
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individuals. Dementia and subacute presenile
dementia both occur in Lyme disease (Refs 146,
149, 194, 195, 196, 197, 198). B. burgdorferi was
first detected in the brains of two AD patients
(Table 1) by MacDonald and Miranda (Ref. 178)
and MacDonald (Ref. 199). This spirochete was
detected in the cerebral cortex by dark-field
microscopy and with a specific antibody against
B. burgdorferi. This species was also detected and
cultivated from the brains of three definite AD
cases in an initial series of 14 AD cases
(Ref. 146). Molecular characterisation, using 16S
rRNA gene sequence analysis, identified these
spirochetes as B. burgdorferi sensu stricto (s.s.)
(Ref. 149). Electron microscopy analysis
confirmed that these spirochetes possess 10–15
endoflagella typical of Borrelia species. Two of
the three AD patients had a positive CSF
serology for B. burgdorferi, and the 31 kDa outer
surface protein A (OspA) band, which is highly
specific for B. burgdorferi, was detected by
western blot in these three AD cases (Ref. 149).
The pathological changes found in the brain
were identical to those occurring in the atrophic
Spirochetes detected in the frontal cortex of neuropathologically confirmed 
Alzheimer disease cases
Expert Reviews in Molecular Medicine © 2011 Cambridge University Press
a b
c d
Figure 2. Spirochetes detected in the frontal cortex of neuropathologically confirmed Alzheimer disease
cases. Spirochetes in an immature senile plaque detected by a cocktail of antibodies against Borrelia
burgdorferi (a), in a mature plaque detected by in situ hybridisation (b, arrows) using Borrelia-specific
probes, and in an amorphous plaque detected by antibacterial peptidoglycan antibody (c). (d) The central
part of panel c at higher magnification. Arrows indicate helical spirochetes with the same morphology as
observed in b. Scale bars: 80 μm (a), 30 μm (b), 80 μm (c), 20 μm (d). Images are from previously published
studies: a,b (Ref. 149); c,d (Ref. 188).
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form of general paresis (Ref. 149). The cortical
distribution of spirochetes in masses or colonies
was identical to those of senile plaques, and the
morphology of individual spirochetes was
identical to those of curly fibres (Ref. 149). B.
burgdorferi antigens colocalised with Aβ in
cortical plaques and in leptomeningeal and
cortical arteries containing amyloid deposits.
Neurofibrillary tangles were also
immunoreactive for B. burgdorferi. OspA and
flagellin genes were detected in AD-type lesions
using in situ hybridisation (ISH) (Fig. 2b). In
additional AD patients with concurrent Lyme
neuroborreliosis, B. burgdorferi-specific antigens
(Ref. 146) and DNA (Ref. 179) were observed.
Using species-specific PCR, B. burgdorferi DNA
was detected in 5 of 16 AD patients tested and
in 1 of 18 controls, all of which also had oral
Treponema spirochetes (Ref. 147). Finally, B.
burgdorferi-specific DNA was detected by both
ISH and PCR in the hippocampus in 7 of 10
pathologically confirmed AD cases (Refs 183,
184) (Table 1).
Pappolla and colleagues (Ref. 185) failed todetect
B. burgdorferi in six AD patients. They stated that
they could not exclude other spirochetes not
detected by their methods. In all other studies
where B. burgdorferi was not detected, evidence is
lacking on whether the analysed AD patients had
Lyme neuroborreliosis or not (Refs 180, 181)
(Table 1). Similarly, the analysis of the serology of
B. burgdorferi alone, as a result of the low
incidence of Lyme dementia compared with AD,
might give false-negative results (Refs 180, 182).
To demonstrate the role of B. burgdorferi, AD
patients with Lyme neuroborreliosis should be
analysed.
Taken together, these observations show that
various authors detected and cultivated various
types of spirochetes from the brains of AD
patients. Coinfection with several types of
spirochetes occurs.
Chlamydophyla pneumoniae
Several authors reported the existence of an
association between C. pneumoniae, an obligate
intracellular respiratory pathogen, and AD
(Refs 144, 200, 201, 202, 203) (Table 2). C.
pneumoniae-specific DNA was detected in the
brains in 90% of sporadic AD patients and in 5%
of controls (Ref. 144) (Table 2). Two mRNAs,
encoding KDO transferase and a 376 kDa
protein, specific to C. pneumoniae, were also
identified in frozen AD brain tissue by reverse
transcriptase-PCR (RT-PCR).
Immunohistochemical analyses of AD brains
showed C. pneumoniae in microglia, perivascular
macrophages and astrocytes, and in about 20%
of neurons (Refs 144, 200, 201, 203, 207, 211).
They were commonly found in brain regions
showing the characteristic neuropathology of
AD (Refs 144, 200, 201). The presence of
C. pneumoniae in the brains of AD patients was
also confirmed by immunoelectron microscopy
using specific monoclonal antibody against
the outer membrane protein of C. pneumoniae.
Electron and immunoelectron microscopy
identified both chlamydial elementary bodies
and reticulate bodies (RBs) (Refs 212, 144). That
the replicative RB form was also detected in
glial cells, neurons and pericytes indicates that a
viable and transcriptionally active form of
the microorganism is present in these cells
(Refs 201, 213, 214, 215). Pleomorphic forms of
C. pneumoniae were also observed (Ref. 213).
C. pneumoniae-specific DNA was detected in the
CSF in a significantly higher number of cases
in AD patients (43.9%) than in controls
(10.6%) (Ref. 202). C. pneumoniae was cultured
from various brain samples of AD patients
originating from different geographic regions of
North America (Refs 144, 201, 215) and was also
isolated from the CSF (Ref. 202). Tor-1 and Phi-1
isolates were characterised by PCR assays
targeting C. pneumoniae-specific genes Cpn0695,
Cpn1046 and tyrP. Two groups, using paraffin-
embedded brain samples, failed to detect
C. pneumoniae in AD or in controls by PCR
(Refs 216, 217). In another study, C. pneumoniae
was detected in 2 of 15 AD cases and in 1 of 5
controls (Ref. 204).
Other bacteria
Propionibacterium acnes, an atypical anaerobic
bacterium, was identified in biopsy specimens of
the frontal cortex in three of four AD patients
and in one of five controls with cerebral tumour.
The P. acnes positive control was an elderly
patient with cardiovascular risk factors and
glioblastoma (Ref. 205). P. acnes was identified
by microbiological methods and by gas
chromatography. The bacterium was cultivated
from frontal cortical biopsy specimens in
Schaedler blood agar, at 35°C, under anaerobic
conditions (Refs 205, 206). P. acnes has long been
considered to be a commensal bacillus of the
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skin. Recent observations showed that P. acnes, the
causative agent of acne vulgaris, is implicated in
various infections, including brain abscesses,
endocarditis, endophthalmitis and osteomyelitis
(Refs 208, 209). P. acnes was also shown to be a
predominant periodontal pathogen (Ref. 218).
By haematogenous dissemination, it can reach
and infect various organs, including the brain.
Stabilisation of the clinical symptoms and
memory improvement were observed in two
AD cases treated with P. acnes-sensitive
cephalosporine combined with enalapril and
oestrogen (Ref. 206). The author pointed to
microangiopathy as the underlying pathology
(Refs 219, 220). Because the number of AD cases
analysed is low, further studies should be
encouraged to determine any association of P.
acnes with AD.
Actinomycetes have also been suggested to be
involved in AD, with an incidence four times
higher than in other pathological conditions
(Ref. 221). Ultrastructural analysis revealed that
the fibronectin-immunopositive fibrillary lesions
in senile plaques, which were negative for
neuronal, glial and macrophage markers, are
compatible with filamentous microorganisms
and might correspond to Actinomycetes
(Ref. 221). It is noteworthy that Actinobacillus
actinomycetemcomitans is a frequent periodontal
pathogen (Ref. 222) and that Nocardia asteroides
was reported to cause Parkinson-like symptoms
in experimental animals (Ref. 223).
Finally, the causative agent of stomach ulcers,
H. pylori (Ref. 125), has also been suggested to
be associated with AD (Refs 224, 225, 226).
Serum IgG and IgA antibodies against H. pylori
occurred in a higher percentage in the group of
30 AD patients compared with 30 controls
(Ref. 224). The difference is statistically
significant as determined by post-hoc
Table 2. Detection of Chlamydophyla pneumoniae and other bacteria in AD
Material Number Method AD Control Refs
C. pneumoniae Brain 38 PCR, EM, IHC,
RT-PCR, Cult
17/19 1/19 144
Brain 25 PCR, IHC 0/25 216
Brain 20 PCR, IHC 0/20 217
Brain 20 PCR, Cult 2/15a 1/5a 204
Brain 21 PCR, ISH 21/21 0/1 200
Brain 52 PCR, Cult,
RT-PCR
20/25 3/27 201
CSF 104 PCR, Cult 25/57 5/47 202
Total
brain
177 P= 4.5 × 10−7
OR= 8.7
CI= 3.1–29.5
60/125 5/52
Brain and
CSF
281 P= 9.8 × 10−11
OR= 7.8
CI= 3.7–17.8
85/182 10/99
Propionibacterium
acnes
Brain 3 Cult 3/4 1/5 219, 220
H. pylori Stomach 80 HC 44/50 14/30 225
AD, number of AD caseswith positive detection/number of AD cases analysed; Control, number of control cases
with positive detection/number of control cases analysed; CSF, cerebrospinal fluid; PCR, polymerase chain
reaction; RT-PCR, reverse transcriptase-PCR; EM, electron microscopy; IHC, immunohistochemistry; Cult,
culture. P, exact value of significance following Fischer test; OR, odds ratio; CI, 95% confidence interval values.
aPositive in at least one of several samples.
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comparison (Ref. 210). An almost twofold higher
prevalence of gastric H. pylori infection was
observed in clinically diagnosed AD patients
and in patients with mild cognitive decline
(Refs 225, 227) than in controls. H. pylori-specific
IgG antibody levels were also significantly
higher in the blood and CSF of AD patients than
in controls (Ref. 226). Additional studies would
be of interest in detecting whether H. pylori is
present in the brain and to analyse the
possibility of a causal relationship between H.
pylori and AD.
Herpes simplex virus type-1 (HSV-1) and
other viruses
HSV-1 is a common neurotropic virus that infects
around 70% of the population after the age of 50
(Refs 150, 228, 229, 230). HSV-1 DNA was
detected (Table 2) in brain samples using ISH in
some elderly patients with dementia (Ref. 231).
Three other studies failed to detect HSV-1 by
ISH in AD or in control brains (Refs 232, 233,
234, 235). Increasing numbers of recent
observations have detected HSV-1 DNA in the
brain in AD (Refs 150, 151, 228, 229, 236, 237,
238). Using PCR, Jamieson et al. (Ref. 150)
observed HSV-1 DNA in the brains of a high
proportion of elderly subjects, with or without
AD, which was absent or less frequent in young
controls (Ref. 228). Several authors showed that
HSV-1 is a significant risk factor (Table 3) when
present in AD patients who are carriers of
APOE ε4 (Refs 236, 237, 238), but this is not
supported by Beffert et al. (Refs 239, 240). In situ
PCR showed that HSV-1 DNA is localised to
senile plaques (Ref. 243). Ninety per cent of
senile plaques in AD and 80% in normal ageing
subjects contained viral DNA (Ref. 241).
Table 3. Detection of HSV-1 in AD
Material Number Method AD Control P value Refs
Brain 6 ISH 2/3 1/3 0.423 231
Brain 5 ISH 0/3 0/2 232
Brain 23 ISH 0/18 0/5 233
Brain 13 ISH 0/8 0/5 234
Brain 6 ISH 0/4 0/2 235
Brain 14 PCR 8/8 6/6 150
Brain 36+ 10 PCR 14/21 9/15 (0/5
middle aged;
0/5 young)
228
Brain 155 PCR 73/98 41/57 0.485 229
Brain 90 PCR 36/46 28/44 0.295 (P< 0.0001,
APOE ε4)
236
Brain 69 PCR 14/46 5/23 0.295 (P< 0.0047,
APOE ε4)
237
Brain 109 PCR 45/61 30/48 (P< 0.0001, APOE ε4) 238
Brain 110 PCR 54/74 26/36 0.82 239, 240
Total
brain
556 210/
344
118/212 P = 0.2152 OR= 1.25
CI = 0.9–1.8
Number of Alzheimer cases with positive detection/number of Alzheimer cases analysed; Control, number of
control cases with positive detection/number of control cases analysed. P, value of significance following
Fischer test; OR, odds ratio; CI, 95%confidence interval values;+, positive; –, negative; AD, Alzheimer disease;
CSF, cerebrospinal fluid; HSV-1, herpes simplex virus type-1; IHC, immunohistochemistry; ISH, in situ
hybridisation; PCR, polymerase chain reaction; APOE ε4: epsilon 4 allele of apolipoprotein E.
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Anti-HSV-1 antibodies as detected in the CSF by
enzyme-linked immunosorbent assay (ELISA)
were also significantly higher in AD patients than
in younger controls, but without a significant
difference between the AD and age-matched
control groups (Ref. 242). Increased titres of HSV-
1 IgGs, which characterise past infection, were
observed in AD cases and age-matched controls,
without a significant difference between the two
groups (Refs 243, 244). In a large prospective
study, in addition to HSV-1 IgG, the presence of
IgM, which characterises active primary infection
or reactivation of the infection, was also assessed
in the sera of 512 elderly patients, initially free
of dementia. During 14 years of follow-up, 77
AD cases were diagnosed. In contrast to IgG,
IgM-positive subjects showed a significantly
higher risk of developing AD, indicating that
reactivation of HSV-1 seropositivity is correlated
with AD (Ref. 245).
Other herpes viruses were also detected in the
brain using PCR: human herpes virus 6 (HHV6)
types A and B, herpes simplex virus type-2
(HSV-2) and cytomegalovirus (CMV). HHV6,
HSV-2 and CMV were observed in 70%, 13%
and 36% of AD patients and in 40%, 20% and
35% of controls, respectively. The differences
between the groups were not statistically
significant (Ref. 246).
In addition to CMV, a possible association
between HLA-BW15 and AD has also been
reported (Ref. 247). A recent study revealed that
elderly subjects with high levels of antibody
against CMV develop more severe cognitive
decline over 4 years (Ref. 248) compared with
controls.
The adenovirus early region 1A (E1A) gene
and its expression using ISH and
immunohistochemistry were analysed in five
AD cases and in two controls. Reactive
microglial cells in both AD (5/5) and control
brain tissue (2/2) showed positive hybridisation
and immunoreactive expression of adenovirus
E1A, indicating a monocyte- or microglia-
mediated entry of adenovirus into the central
nervous system (CNS) (Ref. 249).
Borna disease virus (BDV) was linked to
affective disorders and schizophrenia (Refs 139,
142). A few attempts have been made to analyse
the prevalence of BDV antibodies and BDV p40
gene coding sequences in AD (Refs 250, 251,
252), which did not show an association
(Table 3). Following Borna-virus-induced
infection in APP(Tg2576) transgenic mice, a
reduction of cortical and hippocampal Aβ
deposits was observed (Ref. 253). One
explanation is that the stimulation and
activation of microglia might produce this effect.
The human immunodeficiency virus type-1
(HIV-1) (Ref. 254) is able to induce the biological
hallmarks of AD; however, the virus is present in
the brains of mostly young patients suffering
from acquired immune deficiency syndrome
(AIDS). The virus invades mostly macrophages
and glial cells and the virus itself does not
reproduce the pathological hallmarks of AD.
However, by affecting immune defences, HIV-1
facilitates infection by various pathogens,
including, among others, HSV-1, CMV, C.
pneumoniae andspirochetes (Refs 255, 256, 257, 258).
Correlates of infection risk and AD
Based on the data available on the association of
spirochetes, C. pneumoniae and HSV-1 with AD,
contingency tables were used to analyse the
strength of the association and the risk of
infection in AD. In those studies where all types
of spirochetes were detected using neutral
techniques, spirochetes were observed in the
brain in 90.1% (64/71) of AD cases and were
absent in controls without any AD-type
changes. This difference is significant (Table 1),
and the association remains significant when
cases where spirochetes were analysed in the
blood are also included. The association
between periodontal pathogen spirochetes and
AD is also statistically significant. They were
detected in the brain in 93.7% of AD cases and
in 33.3% of controls. B. burgdorferi was about 13
times more frequent in AD cases than in
controls, a statistically significant difference. It is
noteworthy that B. burgdorferi was detected in
all AD cases with a positive serology or where
spirochetes were cultivated from the brain
(Table 1). Taken together, in all studies where
spirochetes or their specific species (periodontal
Treponema spirochetes or B. burgdorferi) were
detected in the brain, it can be concluded that
the frequency of spirochetes is more than eight
times higher in AD cases (90/131; 68.7%) than in
controls (6/71; 8.41%). That spirochetes were
cultivated from the brains of AD patients
indicates that viable spirochetes are present in
advanced stages of dementia. They can sustain
persisting infection and inflammation and cause
neuronal destruction (Ref. 148).
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The frequency of C. pneumoniae was about five
times higher in AD cases (60/125; 48%) than in
controls (5/52; 9.6%). The difference remains
significant when those cases where C.
pneumoniae was detected in the CSF were also
included (Table 1). That C. pneumoniae was
cultivated from the brain (Refs 200, 213) and
CSF (Ref. 202) and that replicative RBs were
present in glial cells, neurons and pericytes in
AD indicate that this microorganism is also
present in a viable, active form in the brain in AD.
There is no significant difference between the
frequency of HSV-1 detected in the brain in AD
patients compared with age-matched control.
However, a significant difference was observed
between APOE ε4-positive and -negative AD
carriers, as reported by several authors
(Refs 236, 237, 238, 259, 260), except for Beffert
and colleagues (Refs 239, 240). A significant
association of AD with ongoing or reactivated
HSV-1 infection was reported (Ref. 245).
Evidence for a causal role of pathogens
in AD
Additional studies have brought further evidence
in favour of a probable causal relationship
between spirochetes, C. pneumoniae, HSV-1 and
AD. Exposure of primary mammalian neuronal
and glial cells to spirochetes, namely to B.
burgdorferi, which can be cultivated and
propagated in pure culture, generated
thioflavin-S-positive and Aβ-immunoreactive
amyloid plaques and tangle- and
granulovacuolar-like formations in vitro
(Refs 175, 261). In situ, in the spirochete-
induced Aβ plaques, synchrotron infrared
microspectroscopy analysis revealed the
presence of a β-pleated sheet conformation
(Ref. 261). Spirochete-induced increases in Aβ,
APP and phosphorylated tau were all detected
by western blot in infected cell cultures
(Ref. 261). This additional experimental
evidence indicates that spirochetes are able to
induce an AD-type host reaction and reproduce
the defining pathological and biological
hallmarks of AD (Refs 175, 261). Similar in
vitro studies performed on CNS organotypic
cultures, which aim to replace in vivo
experiments, showed identical results
(Ref. 261). Reference B. burgdorferi spirochetes
(strain B31) and those cultivated from the AD
brain (strains ADB1 and ADB2) invaded
neurons and glial cells and induced nuclear
fragmentation in vitro, indicating that the
spirochetes cultivated from the brains of AD
patients are invasive and cause neuronal and
glial damage and apoptosis (Refs 175, 261).
Spirochetes occur in both extra- and
intracellular locations. They invade neurons in
vitro, in primary neuronal cultures (Refs 175,
261), in the cerebral cortex and in the
trigeminal ganglia of AD patients (Refs 146,
147, 148, 149, 175, 183, 184, 261). Historical
observations and illustrations showing that
chronic spirochetal infection can reproduce the
clinical, pathological and biological hallmarks
of AD strongly support a causal relationship
between spirochetal infection and AD
(Refs 114, 115, 124). All these observations
indicate that various types of spirochetes,
including B. burgdorferi and several periodontal
pathogen spirochetes, in an analogous way to
T. pallidum, can cause dementia, cortical
atrophy and the pathological and biological
hallmarks of AD.
Astrocytes and microglia infected in vitro with
C. pneumoniae display inclusions that are
indistinguishable from those characteristic of
active infection of the standard HEp-2 host cell
line (Refs 214, 215). It was reported that chronic
or persistent infection of CNS cells with C.
pneumoniae can affect apoptosis in AD, in both a
pro- and antiapoptotic manner (Refs 203, 214,
215). Furthermore, infection of BALB/c mice by
intranasal inhalation of C. pneumoniae initiated
Aβ1–42 deposits in the brain that resembled
senile plaques (Ref. 262). Antibiotic treatment
following C. pneumoniae infection limited the
number of induced amyloid plaques in vivo
(Ref. 263).
The glycoprotein B (gB) of HSV-1 has a highly
homologous sequence to a fragment of Aβ
(Ref. 264). Synthetic peptides derived from this
region accelerate fibrillar aggregation of Aβ in
vitro. They can self-assemble into fibrils, which
are ultrastructurally indistinguishable from Aβ
and are neurotoxic at a similar dose to Aβ. It
was proposed that HSV-1 might act as a ‘seed’
for senile plaque formation (Ref. 265). It was
also shown that HSV-1 is associated with APP
during its anterograde transport, which might
affect APP degradation and synaptic function
(Ref. 265).
Exposure of cultured cells to HSV-1 results in
increased intracellular Aβ levels in neurons and
glial cells as analysed by immunocytochemistry,
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ELISA andwestern blot. Tau phosphorylationwas
also observed at a number of sites that are
phosphorylated in AD (Refs 266, 267, 268). It
was suggested that the association of viral DNA
and senile plaques is very likely to be causal,
because HSV-1 is able to increase the level of Aβ
in neurons of infected mice in vivo (Ref. 266).
Evidence for underlying mechanisms
Sources and dissemination
Spirochetes, C. pneumoniae and HSV-1 are all able
to invade the brain (Fig. 3) and generate latent and
persistent chronic infection (Refs 144, 145, 146, 147,
148, 149, 228, 229, 269). The strongneurotropismof
spirochetes is well known (Ref. 167). In addition to
haematogenous dissemination, spirochetes can
spread through the lymphatic system and along
nerve fibre tracts (Ref. 167). Periodontal invasive
spirochetes were detected in the trigeminal
ganglia and along the trigeminal nerve
(Ref. 147). They might also propagate along the
fila olfactoria and tractus olfactorius, which
would enable them to reach the CSF, the septal
and hippocampal regions in the earliest stages
of the disease. This would be in harmony with
the olfactory hypothesis (Refs 94, 95, 96) and the
early involvement of the olfactory tract and bulb
(Ref. 97).
Through infected circulating monocytes, C.
pneumoniae can also spread by haematogenous
dissemination and, by crossing the blood–brain
barrier, infect the brain. C. pneumoniae is an
upper respiratory tract pathogen and can reach
the brain through the olfactory system (Ref. 95).
Intranasal inhalation of C. pneumoniae initiated
plaque-like Aβ1–42 deposits in the brain in
BALB/c mice, and C. pneumoniae-specific DNA
was detected by PCR in the olfactory bulb in
AD (Ref. 262).
HSV-1 infection might also reach the brain
through the olfactory system, by infection of
cranial and peripheral nerves and their ganglia
and through haematogenous dissemination
(Refs 270, 271). The virus can reside in the brain
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Figure 3. Sources and dissemination of pathogens associated with Alzheimer disease.
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in a latent form and be reactivated by peripheral
infection, stress or immunosuppression (Ref. 268).
Neuroinflammation and TLR signalling
Persisting, poorly degradable bacterial remnants
in mammalian tissues act as chronic
inflammatory stimuli (Refs 272, 273, 274).
Lipopolysaccharides (LPSs), PGN and various
bacterial lipoproteins elicit a variety of
proinflammatory responses and might represent
an important source of inflammation in AD.
Complex interactions between the innate and
adaptive immune systems have a major role in
infection (Ref. 275). The functions of innate
immunity allow host cells to recognise most
microorganisms, execute proinflammatory
defences and start adaptive immune responses.
Bacteria attach to host cells through a variety of
cell-surface components, including surface
amyloid proteins, which interact with host
proteases (Refs 276, 277, 278, 279, 280, 281, 282,
283). Proteolysis of the extracellular matrix
allows bacteria to penetrate the basement
membrane and invade host cells.
It is the innate immune system that provides the
first line of defence against microorganisms.
Pattern recognition receptors (PRRs), such as
Toll-like receptors (TLRs), recognise unique
structures of invading microorganisms
(Ref. 284). Patients with genetic defects related
to signalling pathways activated by TLRs
frequently suffer from severe recurrent infection
(Refs 285, 286, 287, 288, 289). In the absence of
TLRs, death from experimental sepsis is
significantly enhanced (Ref. 287). Various
bacteria, including spirochetes, activate TLR
signalling and interact with CD14 (Refs 290, 291,
292). T. pallidum and B. burgdorferi or their
synthetic membrane lipoproteins are major
inflammatory mediators (Refs 293, 294) and
activate both the classical and alternative
complement pathways, which opsonise and kill
pathogens without the need for antibody.
Complex interactions between pathogen-
associated molecular patterns (PAMPs), PRRs
and TLR signalling pathways have a major role
in linking innate and adaptive immunity and
maintaining pathogen-free host tissues
(Ref. 275). TLRs activate two major signalling
pathways (Fig. 4). The core pathway activated
by most TLRs leads to the activation of
transcription factor nuclear factor-kappa B (NF-
κB) and the mitogen-activated protein kinases
(MAPKs) p38 and Jun kinase (JNK). The second
pathway is activated by TLR3 and TLR4 and
results in the activation of both NF-κB and
interferon regulatory factor-3 (IRF3), allowing
the induction of another set of inflammatory
genes, including the antiviral interferon-β gene
(IFNB).
Activation of p38 MAPKs during bacterial
infection was also shown to be crucial in the
local production of cytokines such as IL-8
(Ref. 295) and in the development of effective
immune responses in vivo (Ref. 296). Toxin-
induced p38 MAPK activation requires pore
formation and is inhibited by the relief of
osmotic stress.
Pore-forming toxins are the most common class
of bacterial protein toxins and are often important
virulence factors (Ref. 297). Pore-forming bacterial
toxins are typically oligomers of soluble,
monomeric proteins or peptides, which form
transmembrane channels. Channel formation in
the membrane of targeted cells, which triggers
cellular ion imbalance, is a widely used form of
bacterial attack (Refs 298, 299). These pore-
forming bacterial toxins generate calcium-
dependent and lipid-mediated signalling on
host cell surfaces, leading to a variety of events
such as tyrosine phosphorylation (Ref. 300),
actin rearrangement (Ref. 301), NF-κB activation
(Ref. 302) and regulation of gene expression
through histone modification (Ref. 303).
Mammals also use bacterial porin-like proteins
such as perforins as part of their innate immune
defences (Ref. 304). Aβ1–42 was shown to be an
AMP that belongs to the innate immune system.
Toxic oligomers of Aβ1–42 bind to lipid bilayers
of bacterial membranes and enveloped viruses,
triggering Ca2+ influx and bacteriolysis or viral
destruction. Deregulation of the balance
between host cell destruction by pathogens
and pathogen destruction by the host
immune systems will influence the outcome of
infections.
The innate and alternative pathways through
the common membrane attack complex (MAC,
C5b9) cause bacteriolysis (Refs 305, 306, 307).
Cellular and humoral components of the
immune system reactions are both associated
with AD (Refs 98, 99, 100, 101, 102). The
adaptive immune system kills pathogens
through the formation of specific antibodies
directed against invading microorganisms.
Monocytes, macrophages and microglia
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Pore-forming bacterial toxins and bacterial amyloids
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Figure 4. Schematic representation of signalling pathways implicated in host–pathogen interactions in
Alzheimer disease. Pattern recognition receptors (PRRs) recognise conserved structural components of
microorganisms, called pathogen-associated molecular patterns (PAMPs) or ligands, which include
peptidoglycan (PGN), lipoteichoic acid (LTA), flagellin (FLA), bacterial lipoprotein (BLP) and nucleic acid
structures, such as bacterial CpG DNA or viral RNA, unique to bacteria and viruses. Lipopolysaccharide
(LPS) is recognised following its binding to lipoprotein binding protein (LBP). Only Toll-like receptors (TLRs)
have a cytoplasmic domain for signal transduction. Plasma-membrane-localised TLRs include TLR1, TLR2,
TLR4, TLR5, TLR6 and TLR10, whereas endosomal TLRs include TLR3, TLR7, TLR8 and TLR9. TLR9 is
responsible for the recognition of CpG islands of bacterial DNA. Complex interactions between pathogen-
associated molecular patterns (PAMPs), pattern recognition receptors (PRRs) and TLR signalling pathways
have a major role in linking innate and adaptive immunity and maintaining pathogen-free host tissues.
Mammals use antimicrobial peptides (AMPs) as part of their innate immune defences to destroy invading
pathogens. In contrast, in a similar way, pore-forming bacterial surface proteins are also able to destroy
host cells. Evasion of pathogens from destruction by the host immune defences will result in chronic
persistent infection and host cell destruction. APP, amyloid precursor protein; Aβ, amyloid beta; CD14,
cluster of differentiation 14; NF-κB, nuclear factor-kappa B; MALP2, mycoplasma diacylated lipopeptide 2;
p38 MAPK, mitogen-activated protein kinase; JNK, c-Jun kinase; MAC, membrane attack complex; MD2,
lymphocyte antigen 96; Akt, serine/threonine protein kinase Akt1; IRF, interferon regulatory factor; IL,
interleukin; TNF, tumour necrosis factor; COX2, cyclooxygenase 2; IFN, interferon, CREB, cAMP response
element binding.
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participate in both the innate and adaptive
immune responses. When activated, they secrete
chemokines and cytokines and express various
proinflammatory molecules needed for the
efficient removal of pathogens and damaged
cells.
Neuroinflammatory responses that include
activation of glia with marked elevation of
cytokine expression, in particular elevation of
IL-1, are observed in AD, in Down syndrome
fetuses and children before plaque formation,
and also in HIV infection (Refs 99, 308, 309). IL-
1 directs both the in vivo (Ref. 310) and in vitro
synthesis of APP (Ref. 311), thus favouring
senile plaque formation in AD. IL-1
upregulation of ApoE promotes ApoE-mediated
induction of APP (Ref. 312) and MAPK-p38-
mediated tau phosphorylation, in part by
upregulation of MAPK-p38 synthesis and
activation and by favouring the formation of
neurofibrillary tangles (Refs 313, 314, 315). IL-1
also influences neurotransmission because it
increases the synthesis and activation of AChE
(Ref. 316) and induces neuron loss by increasing
caspase 1 (IL-1β cleavage enzyme) activity
(Refs 317, 318). Microglial activation by APP and
release of secreted APP (sAPP) modulated by
apolipoprotein E also have an important role in
the degenerative process of AD (Refs 313, 319).
Activation of microglia with TLR2, TLR4 and
TLR9 ligands increases Aβ ingestion in vitro
(Ref. 320). Furthermore, stimulation of the
immune system through TLR9 in APP
transgenic (Tg2576) mice reduces Aβ deposition
(Ref. 321).
Evasion and establishment of latent and
chronic infection
The ability of spirochetes and C. pneumoniae to
evade destruction by host immune systems and
establish chronic infection is well known. HSV-1
can also remain in a latent state and persist
throughout life in human tissues. In the latent
state, the viral genome is present, but no viral
particles are produced. Viral gene expression
during latency is limited to one locus – the gene
encoding the latency-associated transcript
(Ref. 151).
Pathogens use a broad range of strategies to
overcome antigenic recognition, complement
lysis and phagocytosis. Blockade of the
complement cascade or acquisition of host-
derived complement inhibitors results in their
evasion from complement lysis. This allows
microbial survival and proliferation even in
immune-competent hosts. Complement-resistant
strains of B. burgdorferi possess five complement
regulatory acquiring surface proteins, which
bind host complement inhibitors (Refs 307, 322)
and a CD59-like molecule (Refs 322, 323). A
fragment of HSV-1 glycoprotein C (gC) shares
sequence similarity with host complement
receptor 1 (CR1), showing that viruses can also
escape from attack by the MAC. Bacteria and
viruses protect themselves from destruction by
the host adaptive immune system. B. burgdorferi
induces IL-12, a cytokine recently recognised to
be critical for driving cellular responses
towards the Th1 subset of T helper cells
(Refs 293, 324). This shift retards antibody
induction by Th2 cells against bacteria. These
various ways of evasion allow bacteria to
survive and proliferate in host tissues and
sustain chronic infection.
Iron and nitric oxide
Bacterial cell wall components, including LPSs
and PGNs, are highly resistant to degradation
by mammalian enzymes and persist indefinitely
in mammalian tissues. During chronic exposure,
bacteria and bacterial debris accumulate in
infected host tissues, sustaining chronic
inflammation and slowly progressive cell
damage (Refs 272, 273, 274, 325, 326). Bacteria,
LPSs and PGNs have a variety of biological
actions in mammals (Ref. 327). They not only
are inflammatory cytokine inducers and
activators of complement pathways, but they
also affect vascular permeability (Ref. 328),
induce nitric oxide and free radicals, inhibit
DNA synthesis, and cause apoptosis and
cellular damage (Ref. 329).
Macrophage regulation of immune surveillance
involves iron depletion (Refs 330, 331, 332).
Lactoferrin, which is similar in structure to
transferrin, has a role in natural defence
mechanisms in mammals and is upregulated in
neurodegenerative disorders. Lactoferrin exerts
its anti-inflammatory action by inhibiting
hydroxyl radical formation. This antioxidant
property prevents DNA damage (Ref. 329). By
contrast, free iron abolishes the bactericidal
effects of serum and strongly enhances infection
and bacterial virulence (Refs 329, 330, 331, 332).
Iron has been shown to increase the formation
of reactive oxygen intermediates, resulting in
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lipid peroxidation and subsequent oxidative
damage of proteins and nucleic acids (Refs 330,
331, 332). By affecting T-cell generation, iron
also influences antigen-specific cellular
responses, T-cell functions and the production of
proinflammatory cytokines by macrophages
(Ref. 333). Iron, which has a fundamental role in
infection, also accumulates in senile plaques in
AD (Refs 330, 334, 335, 336).
Activation of macrophages and other host cells
by bacteria or LPS causes inducible nitric oxide
synthase (iNOS) synthesis, which in turn
generates substantial amounts of nitric oxide
from the amino acid L-arginine (Ref. 332). Nitric
oxide is a critical component in the clearance of
bacterial, viral, fungal and parasitic infections
(Ref. 337). In a mouse model, genetic disruption
of iNOS was associated with a significantly
higher risk of dissemination and mortality of
infection (Ref. 338). Pathogens have also evolved
a broad array of strategies to limit nitric oxide
production (Refs 338, 339, 340), which might
contribute to their evasion from host immune
responses (Ref. 340). Nitric oxide also has a
central role in chronic degenerative diseases,
including AD (Ref. 341).
Amyloidogenesis
Amyloidogenesis is the aggregation of soluble
proteins into detergent-insoluble filamentous
structures about 10 nm wide and 0.1–10 μm
long. These amyloid fibrils have distinct
biochemical and biophysical properties,
including resistance to proteinase K treatment,
β-sheet structure and affinity for binding
thioflavin S and Congo Red.
Chronic bacterial infections (e.g. rheumatoid
arthritis, leprosy, tuberculosis, syphilis,
osteomyelitis) are frequently associated with
amyloid deposition. Cortical and vascular
amyloid deposition in the atrophic form of
general paresis, caused by a spirochete
(T. pallidum), as in AD, corresponds to Aβ.
On the basis of previous observations, it has
been suggested that amyloidogenic proteins
might be an integral part of spirochetes and can
contribute to Aβ deposition in AD (Ref. 146). It
was shown that the BH(9–10) peptide on a β-
hairpin segment of B. burgdorferi OspA forms
amyloid fibrils in vitro that are similar to those
in human amyloidosis (Ref. 342). Recent
observations indicate that amyloid proteins
constitute a previously overlooked integral part
of the cellular envelope of many bacteria
(Refs 343, 344, 345, 346). Amyloid fibril
formation not only results in toxic aggregates,
but also provides biologically functional
molecules (Refs 343, 344, 347). Bacterial
amyloids are involved in bacterial cell–cell
interactions, in their attachment to inert solid
surfaces, and in spore and biofilm formation
(Ref. 347). Microbial amyloids, through
interaction with host proteases, also contribute
to bacterial virulence, to colonisation of the host
and to invasion of host cells.
Bacterial LPSs and PGNs are used worldwide
to generate in vitro and in vivo experimental
inflammation and amyloidosis (Ref. 348). LPSs
induce Aβ accumulation, increased APP levels
and hyperphosphorylation of tau in vitro and in
vivo (Refs 261, 349, 350, 351). Increased APP
mRNA in response to LPS was also detected in
the basal forebrain and hippocampus of the rat
(Ref. 349). Aβ deposition occurs in the brains of
rats chronically infused with LPSs (Ref. 349). In
a triple-transgenic mouse model of AD, repeated
challenges with LPSs were shown to exacerbate
CNS inflammation and to cause increased tau
phosphorylation (Ref. 351).
Genetic factors
Host responses to bacterial infections are
genetically controlled. Promoter polymorphisms
in the genes of proinflammatory cytokines are
associated with susceptibility to infection
(Ref. 352). Tumour necrosis factor alpha (TNF-α)
is a critical mediator of host defence against
infection. Polymorphisms in the gene encoding
TNF-α might determine a strong cell-mediated
immune response or a weak or absent cellular
response, which reflects the genetic variability in
cytokine production (Refs 352, 353). In the
absence of cell-mediated immune responses, the
microorganism can spread freely and
accumulate in infected host tissues (Ref. 354).
Accordingly, in Mycobacterium leprae infection,
two distinct phenotypes can be distinguished:
tuberculoid leprosy and the lepromatous
leprosy. In the tuberculoid or paucibacillary
form, there is strong inflammatory infiltration
and the number of microorganisms is low.
Conversely, in the lepromatous or bacillary
form, the inflammatory infiltrates are poor or
absent and the number of M. leprae is high. A
similar polarity in host reactions – the
infiltrative form with strong cell-mediated
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immune responses and few spirochetes versus the
atrophic form, lacking lymphoplasmocytic
infiltrates but with numerous spirochetes –
occurs in response to T. pallidum and B.
burgdorferi infection (Refs 114, 115, 118, 149). The
influence of TNF-α polymorphism on
spirochetal infections has also been
demonstrated by others (Refs 355).
Class II major histocompatibility genes
influence host immune responses to bacterial
and viral infections. The major
histocompatibility complex phenotype of the
antigen-presenting cell can modulate Th1-like
versus Th2-like cell activity against M. leprae and
other pathogens. In general, it has been
acknowledged that human leukocyte antigen
(HLA) DR isotypes are associated with a
protective response, whereas DQ isotypes are
associated with the multibacillary lepromatous
form with a limited cellular response. HLA gene
polymorphism is a dominant marker of
susceptibility to various infections, including B.
burgdorferi infection (Ref. 356). The important
role of the HLA system in controlling cell-
mediated responses suggests that differences in
HLA haplotypes could contribute to the wide
spectrum of immune responses observed in
leprosy and in other infections (Ref. 357). It is
noteworthy that TNF-α and HLA
polymorphisms, which are risk factors for
infection, substantially influence the risk of AD
(Refs 61, 358, 359, 360, 361, 362).
Association between AD pathology and IL-1β
expression patterns (Ref. 363), and between
disease risk and IL-1β gene polymorphisms, has
been reported (Refs 62, 364). Genetic variation in
the expression of microbial PRRs, including
TLRs, and CD14 gene polymorphisms
predispose to various infections and are also
associated with AD (Refs 365, 366).
Genetic mutations in APP, PS1 and PS2 are
related to the processing of APP (Ref. 39).
Because APP has an important role in the
regulation of immune system reactions and in T-
cell differentiation (Refs 16, 17, 18), genetic
defects in such genes should also result in
increased susceptibility to infection.
APOE ε4 enhances the expression of
inflammatory mediators (Refs 367, 368) and has
a modulatory function in susceptibility to
infection by various bacteria, viruses and
protozoa (Refs 367, 368, 369, 370, 371, 372).
APOE genotyping of three AD cases, where B.
burgdorferi was detected and cultivated from the
brain, showed that two of them were APOE ε4
carriers. The low number of cases does not
allow any conclusion for an eventual link
between spirochetal infection and the APOE ε4
allele (Ref. 149). Sixty-four per cent of AD cases
with positive C. pneumoniae PCR had at least
one APOE ε4 allele (Ref. 207). ISH and
quantitative real-time PCR analyses indicated
that the number of C. pneumoniae-infected cells
and the bacterial load in affected brain regions
of APOE ε4 carriers in AD were significantly
higher compared with those lacking that allele
(Ref. 200). Furthermore, HIV-1-infected subjects
carrying the APOE ε4 allele have higher
recorded levels of dementia (Ref. 369), and the
ε4 allele has also been shown to modulate HSV-
1 infection (Refs 240, 259, 260, 371).
Outstanding research questions and
conclusions
The analysis of all positive and negative data
available in the literature on the association of
pathogens with AD indicates a statistically
significant association between various types of
spirochetes, C. pneumoniae and AD. There is no
significant difference between the frequency of
HSV-1 in AD cases compared with age-matched
controls. However, several authors found a
significant difference between the frequencies of
HSV-1 in APOE ε4 carriers and noncarriers. The
occurrence of positive anti-HSV-1 IgM was
reported to be a risk factor for AD (for a recent
review, see Ref. 373).
Lesions that are similar to senile plaques,
neurofibrillary tangles and neuropil threads, and
granulovacuolar degeneration, accumulation of
Aβ, increased APP levels and phosphorylation
of tau have all been induced by exposure of
mammalian neuronal and glial cells and CNS
organotypic cultures to spirochetes. Aβ-positive
plaques were induced by inhalation of C.
pneumoniae in mice in vivo, and exposure to
HSV-1 increased the Aβ level and produced tau
phosphorylation in neurons in vitro and in vivo.
Through TLRs and other PRRs, pathogens or
their toxic components induce gene expression
and activation of proinflammatory molecules by
host cells. Both the classical and alternative
complement pathways are activated in AD.
MAC(C5b-9), which is intended to lyse bacteria
or encapsulated viruses, and activated microglia
that are designed to clean up debris and foreign
expert reviews
http://www.expertreviews.org/ in molecular medicine
18
Accession information: doi:10.1017/S1462399411002006; Vol. 13; e30; September 2011
© Cambridge University Press 2011
E
m
er
g
in
g
ro
le
s
o
f
p
at
ho
g
en
s
in
A
lz
he
im
er
d
is
ea
se
https://doi.org/10.1017/S1462399411002006
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 16:30:39, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
bacteria are both associated with cortical AD
lesions.
Evasion of pathogens from host defence
reactions results in sustained infection and
inflammation. The microorganisms and their
toxic components can be observed in affected
brains, along with host immunological responses.
Spirochetes, C. pneumoniae and HSV-1
disseminate from the primary site of infection to
the brain usually through systemic infection. As
in syphilis, systemic infection and inflammation
precede the development of dementia by years or
decades. Detection of infection in its early,
peripheral stage can hamper its dissemination to
the CNS and prevent dementia. Consequently,
peripheral infections can have a role in the
initiation and progression of neurodegeneration
in AD (Refs 146, 374, 375, 376). Worsening
of peripheral and systemic infection will
deteriorate CNS involvement. One example is
periodontitis, which is caused mostly by Gram-
negative bacteria, including periodontal
spirochetes, which represents a risk factor for AD
(Refs 156, 377).
It is important to consider that several types of
spirochetes and several types of pathogens can
occur in AD. Coinfection of B. burgdorferi with
various periodontal spirochetes (Ref. 147) or
with T. pallidum (Ref. 378) is well documented.
T. pallidum frequently coinfects with other
bacteria and herpes viruses in syphilis (Ref. 167).
In Lyme disease, coinfection of B. burgdorferi
with C. pneumoniae and HSV-1, which are also
associated with AD, can be observed.
Coinfection by several microorganisms can
accelerate the degenerative process, exacerbate
CNS damage and worsen dementia.
An infectious origin of AD is in harmony with
recent observations showing that Aβ belongs to
the group of AMPs, which are potent, broad-
spectrum bactericides targeting Gram-negative
and Gram-positive bacteria, enveloped viruses,
fungi and protozoans (Ref. 31). Aβ has the
capacity to associate with lipid bilayers of
bacterial cell membranes and to exert
antimicrobial activity by membrane
permeabilisation and by alteration of calcium
homeostasis (Refs 31, 379). The microtubule-
binding site of tau protein also exhibits
antimicrobial properties (Ref. 380).
Inflammation has a primordial role in the
elimination of invading pathogens and infected
host cells. If infection is eradicated, it helps the
healing process. Some proinflammatory
molecules, such as cytokine IL-1β, in addition to
their harmful effects, have a beneficial and
protective effect (Ref. 381). Therefore, long-term
use of anti-inflammatory drugs alone might
weaken the elimination of pathogens and
facilitate their evasion, survival and slowly
progressive proliferation. Combined antibiotic,
antiviral and anti-inflammatory therapy is
suggested as the treatment of choice.
In conclusion, the data available indicate that
infectious agents can initiate the degenerative
process in AD, sustain chronic inflammation,
and lead to progressive neuronal damage and
amyloid deposition. The accumulated
knowledge, views and hypotheses proposed to
explain the pathogenesis of AD fit well with an
infectious origin of the disease. The outcome of
infection is determined by the genetic
predisposition of the patient, by the virulence
and biology of the infecting agent, and by
various environmental factors, such as exercise,
stress and nutrition.
More attention and support is needed for this
emerging field of research. Infection starts long
before the manifestation of dementia; therefore,
an adequate treatment should start early. Because
antibacterial, antiviral and anti-inflammatory
therapy is available, as in syphilis, one could
prevent and eradicate dementia. The effect on the
suffering of patients and on the reduction of
healthcare costs would be considerable.
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Figure 1. Distribution of spirochetes in the atrophic form of general paresis and in the frontal cortex of an
Alzheimer disease (AD) patient with Lyme neuroborreliosis.
Figure 2. Spirochetes detected in the frontal cortex of neuropathologically confirmed Alzheimer disease cases.
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Figure 4. Schematic representation of signalling pathways implicated in host–pathogen interactions in
Alzheimer disease.
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